DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

TreatmentTrends: US Nephrology (BMM and Anemia) Q3 2013

This quarterly report series covers the management of dialysis and mid-late stage CKD patients from the perspective of nephrologists. Emphasis is on anemia management (ESAs and IV Iron), calcium-phosphorus metabolism (phosphate binders) and secondary hyperparathyroidism (vitamin D and calcimimetic agents).
TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. They evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players

Questions Answered in This Report:

  • Understand nephrology patient load and practice demographics

  • Assess current and expected treatment prevalence for renal anemia and bone and mineral metabolism agents among dialysis and later stage CKD patients, as well as brand utilization within each drug class

  • Understand the most important product attributes by product class and the key advantages and disadvantages associated with each product

  • Assess the variance in attitudes among nephrologists with regard to different treatment approaches and disease awareness issues such as beliefs about ESA safety, calcium load, complications of SHPT, and hyperphosphatemia

  • Compare sales and messaging efforts of companies with products in the renal anemia and bone and mineral metabolism space

  • Assess awareness of and interest in renal products in development (Zerenex, Bardoxolone, HIF-PH Inhibitors, Soluble Ferric Pyrophosphate, etc.)


Sample Frame & Methodology:

45 minute online quantitative survey with several open-ended questions for qualitative feedback

200 nephrologists complete the survey in Q1, Q2, and Q3 (100 complete the bone and mineral section and 100 complete the renal anemia section)

300 U.S. nephrologists in the Q4 wave

Nephrologist Screening Criteria:

In practice between 2 and 30 years

Minimum of 50 dialysis or 100 CKD-ND (Stage 3 and 4) patients under management


- Final report in PowerPoint format

- Complete set of frequency tables, summary statistics, and cross tabulations

- Proprietary slide deck and frequency tables

- Clients purchasing prior to fielding will have the opportunity to include up to three proprietary questions in each wave

- Responses to proprietary questions will be provided only to those sponsors and will not be included in the syndicated version of the report but provided under separate cover

- Custom ad-hoc analysis available upon request with purchase of the report

- Access to analyst team for presentation or to address questions

Product Coverage:

Marketed Products: Epogen, Aranesp, Pro-crit, Venofer, Ferrlecit, Nulecit, Feraheme, INFeD, Dexferrum, Sensipar, Zemplar, Hec-torol, Calcijex, Renagel, Renvela, PhosLo, Phoslyra, Fosrenol

In development: Zerenex, HIF inhibitors, Soluble Ferric Pyrophosphate, and others

Related Reports:

- TreatmentTrends®: Chronic Kidney Disease

- TreatmentTrends®: Diabetic Nephropathy

- TreatmentTrends®: Bone and Mineral (EU)

- TreatmentTrends®: Renal Anemia (EU)

- ChartTrends®: Bone and Mineral in Dialysis

- ChartTrends®: Bone and Mineral in CKD-ND

- ChartTrends®: Renal Anemia in Dialysis

- ChartTrends®: Renal Anemia in CKD-ND

- CKD Pharmacor